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Introduction
Orolingual angioedema can occur during alteplase ther-
apy in patients with acute ischemic stroke [3, 6]. In most
patients,orolingual angioedema was mild and transitory
[3]. In contrast to intracerebral hemorrhage as a major
concern in thrombolysis, life-threatening orolingual an-
gioedema as a complication of alteplase treatment in
stroke patients is hardly mentioned. Alteplase-triggered
angioedema seems to be associated with angiotensin-
converting enzyme (ACE) inhibitors [3]. However, al-
teplase-triggered angioedema has also been reported in
patients never exposed to ACE-inhibitors [6]. In view of
these data, the present report has the following objec-
tives. First, to warn of the potentially life-threatening
complication of orolingual angioedema. Second, to pre-
sent CT images of the tongue which exclude lingual
hematoma despite oral bleeding. Third, to estimate the
frequency of orolingual angioedema among stroke pa-
JO
N
 1789
■ Abstract Background Orolin-
gual angioedema can occur during
thrombolysis with alteplase in
stroke patients. However, data
about its frequency, severity and
the significance of concurrent use
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of angiotensin-converting-enzyme
inhibitors (ACEi) are sparse. Objec-
tive (1), to alert to the potentially
life-threatening complication of
orolingual angioedema. (2), to pre-
sent CT-scans of the tongue which
exclude lingual hematoma. (3), to
estimate the frequency of orolin-
gual angioedema. (4), to evaluate
the risk associated with the con-
current use of ACEi. Methods Sin-
gle center, databank-based obser-
vational study on 120 consecutive
patients with i. v. alteplase for acute
stroke. Meta-analysis of all stroke
studies on alteplase-associated an-
gioedema, which provided detailed
information about the use of ACE-
inhibitors. Across studies, the Peto
odds ratio of orolingual an-
gioedema for “concurrent use of
ACEi” was calculated. Results
Orolingual angioedema occurred
in 2 of 120 patients (1.7 %, 95 % CI
0.2–5.9 %). Angioedema was mild
in one, but rapidly progressive in
another patient. Impending as-
phyxia prompted immediate intu-
bation. CT showed orolingual
swelling but no bleeding. One of 19
(5 %) patients taking ACEi had
orolingual angioedema, compared
to 1 of 101 (1 %) patients without
ACEi. Medline search identified
one further study about the occur-
rence of alteplase-associated an-
gioedema in stroke patients strati-
fied to the use of ACEi. Peto odds
ratio of 37 (95 % CI 8–171) indi-
cated an increased risk of alteplase-
triggered angioedema for patients
with ACEi (p < 0.001). Conclusion
Orolingual angioedema is a poten-
tially life-threatening complication
of alteplase treatment in stroke pa-
tients, especially in those with
ACEi. Orolingual hematoma as dif-
ferential diagnosis can be excluded
by CT-scan.
■ Key words thrombolysis · acute
ischemic stroke · tissue
plasminogen activator ·
complication · angioedema
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tients treated with alteplase. Fourth, to estimate the risk
associated with the concurrent use of ACE-inhibitors.
Methods
The Basel Stroke Unit program includes a prospective stroke registry
and defines stroke management pathways. Intravenous thrombolysis
with alteplase has been applied to all patients fulfilling criteria
adapted from the NINDS-trial. Alteplase administration and moni-
toring for 24-hours has been performed on an intensive care unit
(ICU) for all patients. For each patient, demographic and clinical data
including concurrent medication, complications, and functional out-
come have been recorded in the thrombolysis databank. Based on
these data, we determined the percentage (± 95 %-CI) of orolingual
angioedema. Fisher’s exact test was used to compare the frequency of
orolingual angioedema among patients who concurrently took ACE-
inhibitors versus those who did not.
In addition, we performed a Medline search to identify all studies
reporting on the frequency of orolingual angioedema in alteplase-
treated stroke patients with additional information about the con-
current use of ACE-inhibitors. We calculated a weighted estimate of
the odds of alteplase-triggered angioedema comparing patients with
versus without concurrent ACE-inhibitors across studies using the
Peto odds ratio method.
Results
During 6 years (June 1998 to May 2004), 120 stroke pa-
tients received alteplase. Mean age was 66 (± 14) years.
Median NIH-stroke-scale-score was 14. Nineteen pa-
tients (16 %) took ACE-inhibitors, 31 (26 %) betablock-
ers, 14 (12 %) calcium channel blockers, 13 (11 %) AT2-
blockers, and 53 (44 %) antiplatelets, when receiving
alteplase. Orolingual angioedema was observed in 2 of
120 patients (1.7 %, 95 %-CI 0.2–5.9 %). In both patients,
orolingual angioedema was bilateral and occurred 30
minutes after alteplase application had started. In one
patient, orolingual angioedema was mild and disap-
peared spontaneously within three hours. In another pa-
tient, lingual swelling was rapidly progressive. Impend-
ing asphyxia prompted immediate intubation. The
observation of mild bleeding in the mouth pointed to
the possibility of lingual hematoma. CT confirmed an-
gioedema and excluded lingual hematoma (Fig. 1).
Steroids and antihistaminics were used and orolingual
angioedema decreased gradually. In both patients, CT
prior to thrombolysis showed early signs of insular in-
farction on the left.
The patient with severe angioedema took ACE-in-
hibitors.The one with mild angioedema did not.The fre-
quency of orolingual angioedema among patients tak-
ing ACE-inhibitors was 5 % (1/19) compared with 1 %
(1/101) in patients without concurrent use of ACE-in-
hibitors (p = 0.1).
Medline search revealed one further study with de-
tailed information about the use of ACE-inhibitors for all
alteplase-treated stroke patients [3].Across both studies,
the Peto odds ratio of 37 (95 %-CI 8–171) indicated an in-
creased risk of alteplase-triggered angioedema for pa-
tients taking ACE-inhibitors (p < 0.001)(Fig. 2).
Discussion
Our study yielded the following results. (1) Orolingual
angioedema can become a life-threatening complication
of alteplase therapy for stroke. (2) Lingual hematoma as
important differential diagnosis can be excluded by CT.
(3) Orolingual angioedema occurred in 1–2 % of al-
teplase-treated stroke patients. (4) Patients taking ACE-
inhibitors exhibit an increased risk of orolingual an-
gioedema during alteplase treatment for acute stroke.
Orolingual angioedema, though mild and sponta-
neously reversible in most patients [3] can have a rapidly
progressive course. Upper airway obstruction with im-
pending asphyxia can occur suddenly, requiring urgent
intubation or even cricothyroidotomy. As a practical
consequence of this potentially life-threatening compli-
cation,we continue administering alteplase in stroke pa-
tients exclusively in the ICU, where close monitoring as
well as immediate intubation is always available.
Lingual hematoma as the most important differential
diagnosis of acute tongue swelling during thrombolysis
was observed during alteplase therapy. However, imag-
ing data were missing in this report [7]. To our knowl-
edge, this is the first report of CT findings of the tongue,
which excluded lingual hematoma and confirmed an-
gioedema as underlying pathology for the clinically ob-
served lingual swelling in alteplase-treated stroke pa-
tients.
We observed orolingual angioedema during alteplase
therapy for stroke with a frequency of 1.7 %. Because of
a wide 95 % confidence interval (0.2–5.9 %) the true in-
cidence rate might even be higher. Others have reported
similar frequencies ranging from 0.9 % [6] to 5.1 % [3].
Although these frequencies may reflect a publication
bias, the risk of orolingual angioedema during alteplase
treatment for stroke is likely to be higher than the
< 0.02 % frequency estimated for the same agent used in
myocardial infarction [2]. Such a discrepancy may be
explained by brain infarcts causing injury to the auto-
nomic nervous system which enhances the susceptibil-
ity to angioedema [3, 6]. Such a hypothesis would also
explain why angioedema in several patients (but not in
ours) was unilateral [3, 5]. The observation that both of
our patients had early signs of insular infarction cor-
roborates previous findings indicating that ischemic in-
jury of the insular cortex may play a role in the genesis
of angioedema [3].
Orolingual angioedema associated with alteplase
which is a recombinant tissue plasminogen activator
(rtPA) has been attributed to an increased bradykinin
production [3,4].Tissue plasminogen activator converts
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plasminogen to plasmin, which in turn cleaves
bradykinin from high-molecular-weight kininogen [4].
Angioedema associated with ACE-inhibitors is caused
by a reduced clearance of bradykinin due to ACE-in-
hibitors. In addition, neurokinins (e. g. substance P) are
also mediators of angioedema formation and airway in-
flammation [1]. By the use of ACE-inhibitors, the level of
neurokinins increases. Furthermore, neurokinins,
bradykinin as well as its active metabolite des-Arg9-
bradykinin are likely to interact in processes leading to
angioedema (i. e., vasodilatation, plasma extravasation,
mucosal edema) [1]. In patients who take ACE-in-
hibitors and receive alteplase treatment, the combina-
tion of rtPA-mediated increase in bradykinin release [4]
and an ACE-inhibitor-mediated decrease in bradykinin
metabolism together with increased neurokinin levels
may thus increase the probability for angioedema.These
pathophysiological considerations might explain why
ACE-inhibitors increased the risk of orolingual an-
gioedema in alteplase-treated stroke patients [3], as in-
dicated by the high odds ratio [37]. However, this num-
ber should be interpreted cautiously, because its
calculation is based on just two studies. Furthermore,
the 95 % confidence interval is wide [8–171]. Thus, fu-
ture studies are warranted to improve the accuracy of
risk estimation for angioedema in stroke patients with
ACE-inhibitors who receive alteplase.
In conclusion, alteplase-triggered orolingual an-
gioedema can become life-threatening and is not a neg-
ligible complication in stroke patients, especially in
Fig. 1 (a) transaxial CT at the level of the base of the tongue shows diffuse swelling of the mouth floor, base of the tongue and oropharynx. Hyperdense areas or anatom-
ical distortion indicating hemorrhage were absent. Note the minimal space for the endotracheal tube. (b) Sagittal midline 2D multiplanar reconstruction of multislice CT
scan shows diffuse swelling of the tongue up to the epiglottic level
a b
Fig. 2 Peto odds ratio for orolingual angioedema during alteplase-treatment in acute stroke comparing patients with ACE-inhibitors versus those without
ACE inhibitors no-ACE inhibitors Peto OR Weight Peto OR
Study n/N n/N (95 % CI Fixed) % (95 % CI Fixed)
Basel 1/19 1/95 16.8 11.26 (0.27, 471.93)
Calgary 7/35 2/141 83.2 45.05 (8.43, 240.66)
Total (95% CI) 8/54 3/236 100.0 35.71 (7.74, 164,74)
Test for heterogeneity chi-square = 0.44, df = 1, p = 0.51
Test for overall effect z = 4.58, p = 0.00001
0.001 0.02 1 50 1000
Favours treatment Favours control
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those taking ACE-inhibitors. Orolingual hematoma as
differential diagnosis can be excluded by CT.
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